As per Fortune Business Insights, the global Glycoengineering Market was valued at USD 0.85 billion in 2025 and is projected to reach UUSD 0.98 billion in 2026, growing from USD 3.20 billion by 2034 at a CAGR of 15.9% during 2026–2034.
The Glycoengineering Market is emerging as an important area within biologics development as companies increasingly seek controlled glycosylation to improve therapeutic efficacy, stability, safety, consistency, and manufacturing control.
Glycoengineering modifies the glycosylation of recombinant proteins through cellular genetic technologies and in vitro enzymatic methods. The market is supported by increasing development of monoclonal antibodies, biosimilars, vaccines, recombinant proteins, and cell and gene therapies. Growing demand for controlled glycan structures is encouraging pharmaceutical and biotechnology companies to adopt glycoengineering platforms, analytical workflows, and specialized services. Strategic partnerships and new product launches are also strengthening the market landscape.
The market is being driven by the need to improve the performance and quality of biologics. Glycosylation can influence immune activity, stability, safety, therapeutic efficacy, and product consistency. However, controlling glycan structures remains technically complex because glycosylation can vary according to cell lines, culture conditions, process parameters, scale-up methods, and manufacturing sites. This complexity increases the need for advanced analytical tools, skilled personnel, optimization, and comparability testing.
For detailed market insights, visit the Glycoengineering Market reports: https://www.fortunebusinessinsights.com/glycoengineering-market-119212
For request sample reports: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/glycoengineering-market-119212